Quoin Pharmaceuticals Ltd. announced recruitment of three additional patients in its investigator led pediatric Netherton Syndrome (NS) study as well as highly positive 9 month clinical data from the first pediatric patient in the study. After 9 months of continued whole body application of QRX003, the subject's skin remains completely healed demonstrating the durability of ongoing daily treatment with the product. At baseline, prior to initiation of treatment with QRX003, the subject' skin had an Investigator's Global Assessment (IGA) of 4, on a scale of 0-4 where 4 is the most severe score possible.
With no need for previously required medications, such as antibiotics, antivirals, antihistamines and glucocorticoids, and zero nightly sleep disturbance, treatment with QRX003 has truly been completely life transforming for this little girl. Second, announced the recruitment of three additional NS subjects in Austria and Ireland. The company believe that the clinical data from these subjects will continue to demonstrate positive clinical outcomes of QRX003 in NS without adverse events.
